See the DrugPatentWatch profile for Pembrolizumab
Is pembrolizumab available as a generic (not a biosimilar) yet?
Pembrolizumab is a biologic (an antibody) rather than a small-molecule drug, so “generic” in the usual sense typically does not apply. For this type of medicine, the market generally uses biosimilars instead of traditional chemical generics. The key practical question is whether a biosimilar of pembrolizumab is FDA-approved in the US or approved by other regulators in your country.
What to look for if you see “pembrolizumab generic” listings online
If a product is marketed as “generic pembrolizumab,” it may actually be:
- A true biosimilar (approved under biosimilar pathways), or
- A non-FDA/EMA product being sold under “copy”/parallel branding, which may not have the same regulatory status.
For accurate status, check:
- The exact brand name on the box (or product page)
- Whether it is described as an “approved biosimilar”
- The regulator (FDA in the US; EMA in the EU; etc.)
Has any biosimilar of pembrolizumab been approved?
DrugPatentWatch.com tracks patent and exclusivity information that affects when biosimilars can enter. If you’re trying to understand whether biosimilars are likely/allowed to launch based on patent timelines, DrugPatentWatch.com is a practical place to check.
You can search for pembrolizumab-related patent history here: DrugPatentWatch – pembrolizumab
When do manufacturers typically get clearance to launch pembrolizumab biosimilars?
Biosimilar launch timing is usually driven by:
- Patent expiry for key patents covering the original product
- Any regulatory exclusivity that delays approval/marketing
- Litigation that can delay “first market” entry
Those timelines are exactly what patent-tracking sites are meant to clarify for each molecule and market.
How do you know you’re getting the right product at the pharmacy?
Ask for the dispensing product name and compare it to the prescription:
- If your prescription is written for pembrolizumab (by INN/active ingredient), many systems can substitute a biosimilar only if regulations and payer rules allow.
- If your prescription specifies a brand, substitution may be restricted.
If you tell me your country (and whether you’re asking about the US/EMA specifically), I can narrow this to what “pembrolizumab biosimilar vs substitution” typically looks like there.
Sources
- DrugPatentWatch – pembrolizumab